EP
COGT icon

Essential Partners’s Cogent Biosciences COGT Stock Holding History

Essential Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6K Buy
351
+154
+78% +$5.39K 0.01% 1074
2026
Q1 		$7.58K Hold
197
– – ﹤0.01% 1378
2025
Q4 		$7K Buy
197
+8
+4% +$225 ﹤0.01% 1298
2025
Q3 		$2.71K Buy
189
+45
+31% +$533 ﹤0.01% 1686
2025
Q2 		$1.03K Buy
+144
New +$798 ﹤0.01% 1502

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Essential Partners's COGT Position: Q2 2026 in Review

Essential Partners increased its Cogent Biosciences (COGT) stake by 78% in Q2 2026, buying an estimated $5.39K and bringing the position to 351 shares worth $13.6K. The position accounts for 0.01% of the portfolio, ranked #1074.

Essential Partners first reported a position in COGT in Q2 2025 and has held it in 5 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Essential Partners held 351 shares of Cogent Biosciences worth $13.6K as of Q2 2026.
  • Essential Partners bought 154 Cogent Biosciences shares in Q2 2026, an estimated $5.39K.
  • Cogent Biosciences made up 0.01% of Essential Partners's portfolio in Q2 2026, its #1074 holding.
  • Essential Partners first reported a position in Cogent Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.